GSK has shared the data behind its phase 3 liver disease win, revealing patients on linerixibat reported reductions in ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

In a 286-patient Phase 2 trial, elraglusib combined with gemcitabine/nab-paclitaxel achieved a statistically significant ...

which was acquired by GSK when it took over Tesaro in a $5.1 billion deal agreed in 2019, along with PARP inhibitor Zejula (niraparib). There are a number of other TIM-3 targeting drugs coming ...

The London-based pharmaceutical company said in a phase 3 trial, primary and key secondary endpoints were met, which demonstrated a "rapid, significant and sustained improvement" in cholestatic ...